A Phase 1 interventional study of CC-97489 and Placebo in Healthy Volunteers, sponsored by Celgene. Terminated at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-14.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the safety, tolerability, of CC-97489
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
First submitted after Celgene became part of Bristol-Myers Squibb.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CC-97489
Other: Placebo
Specified dose on specified days
Also known as: BMS-986368
Specified dose on specified days
Incidence of Adverse Events (AEs)
Time frame: 28 days after the last dose
Incidence of Serious Adverse Events (SAEs)
Time frame: 28 days after the last dose
Number of participants with clinically significant changes in electrocardiogram parameters
Time frame: Day 21
Incidence of clinically significant changes in vital signs: Body temperature
Time frame: Day 21
Incidence of clinically significant changes in vital signs: Respiratory rate
Time frame: Day 21
Incidence of clinically significant changes in vital signs: Blood pressure
Time frame: Day 21
Incidence of clinically significant changes in vital signs: Heart rate
Time frame: Day 21
Incidence of clinically significant changes in clinical laboratory results: Hematology tests
Time frame: Day 18
Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests
Time frame: Day 18
Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests
Time frame: Day 18
Pharmacokinetics - Maximum observed plasma concentration (Cmax)
Time frame: Up to 96 hours after the last dose of study drug
Pharmacokinetics - Minimum plasma drug concentration (Cmin)
Time frame: Up to 96 hours after the last dose of study drug
Pharmacokinetics - Time to maximum observed plasma concentration (Tmax)
Time frame: Up to 96 hours after the last dose of study drug
Pharmacokinetics - Area under the plasma concentration (AUC)-time curve from time zero extrapolated to infinity (AUC0-∞)
Time frame: Up to 96 hours after the last dose of study drug
Pharmacokinetics - Area under the plasma concentration-time curve from time zero to time t, where t is the time point of the last measurable concentration (AUC0-t)
Time frame: Up to 96 hours after the last dose of study drug
Pharmacokinetics - Area under the plasma concentration-time curve from time zero to 24 hours postdose (AUC0-24)
Time frame: Up to 96 hours after the last dose of study drug
Pharmacokinetics - Area under the plasma concentration-time curve from time zero to tau (τ) where τ is the dosing interval (AUC0- 0-τ)
Time frame: Up to 96 hours after the last dose of study drug
Pharmacokinetics - Terminal elimination half-life in plasma (t½,z)
Time frame: Up to 96 hours after the last dose of study drug
Pharmacokinetics - Apparent total plasma clearance when dosed orally (CL/F)
Time frame: Up to 96 hours after the last dose of study drug
Pharmacokinetics - Apparent total volume of distribution when dosed orally (Vz/F)
Time frame: Up to 96 hours after the last dose of study drug
Pharmacokinetics - Ratio of accumulation based on Day 1 and Day 14 AUC0- 0-τ and Cmax, as appropriate (Rac)
Time frame: Up to 96 hours after the last dose of study drug
Pharmacodynamics - Evaluation of monoacylglycerol lipase (MGLL) enzymatic inhibition by CC-97489 in peripheral blood mononuclear cells (PBMCs)
Time frame: Up to 168 hours after the last dose of study drug
Pharmacodynamics: Peripheral blood mononuclear cell (PBMC) fatty acid amide hydrolase (FAAH) inhibition
Time frame: Up to 168 hours after the last dose of study drug
Pharmacodynamics - Measurement of : plasma and whole-blood anandamide (AEA) levels
Time frame: Up to 168 hours after the last dose of study drug
Pharmacodynamics - Measurement of plasma and whole-blood 2-arachidonoylglycerol (2-AG) levels
Time frame: Up to 168 hours after the last dose of study drug
Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.celgene.com
Ran from Mar 2020 to primary completion in Jul 2022, 27 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Irafamdastat